Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Show more

55 Collins Street, Melbourne, VIC, 3000, Australia

https://www.mesoblast.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

2.01B

52 Wk Range

$13.05 - $21.50

Previous Close

$15.48

Open

$15.17

Volume

27,911

Day Range

$14.98 - $15.17

Enterprise Value

2.078B

Cash

47.39M

Avg Qtr Burn

N/A

Insider Ownership

5.81%

Institutional Own.

3.27%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYONCIL™ (Remestemcel-L) Details Acute graft-versus host disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REVASCOR® (Rexlemestrocel) Details Pediatric Hypoplastic Left Heart Syndrome (HLHS)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rexlemestrocel-L (Rexlemestrocel-L) (Mesenchymal Precursor Cells) Details Prevention Of Life-Threatening Gastrointestinal Bleeding In End-Stage Heart Failure Patients With A Left Ventricular Assist Device (LVAD)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REVASCOR® (Rexlemestrocel) Details Ischemic CHF with reduced ejection fraction (HFrEF) and inflammation	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rexlemestrocel Details Chronic lower back pain (CLBP)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ryoncil/Remestemcel-L-Rknd (Remestemcel-L-Rknd) (Mesenchymal Stromal Cells) Details Steroid-Refractory Acute Graft-Versus-Host Disease In Adults	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ryoncil/Remestemcel-L-Rknd (Remestemcel-L-Rknd) (Mesenchymal Stromal Cells) Details Duchenne Muscular Dystrophy	IND Acceptance decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Remestemcel-L (mesenchymal stem cells) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.